Stockwinners Market Radar for May 10, 2019 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

17:39 EDT Bristow Group trading halted, news pending

17:37 EDT Weatherford plans to restructure through Chapter 11 filing - Weatherford said in a regulatory filing, "Due to the highly competitive nature of our business and the continuing losses we incurred over the last few years, we continue to reduce our overall cost structure and workforce to better align our business with current activity levels. The ongoing transformation plan, which began in 2018 and is expected to extend significantly beyond the originally planned year-end 2019 target, includes a workforce reduction, organization restructure, facility consolidations and other cost reduction measures and efficiency initiatives across our geographic regions. In connection with the Transformation Plan, we recognized restructuring and transformation charges of $20M in the first quarter of 2019, which include severance charges of $2M, other restructuring charges of $14M and restructuring related asset charges of $4M. In the first quarter of 2018 we recognized restructuring charges of $25M, which included severance charges of $11M and other restructuring charges of $14M. Other restructuring charges in both periods included contract termination costs, relocation and other associated costs." The company added that it expects to reach an agreement to the principal terms of a proposed financial restructuring of the company. The transaction is contemplated to be implemented through a prepackaged Chapter 11 plan of reorganization to be implemented through the cases.

17:32 EDT Point72 Asset Management reports 5.4% passive stake in Intersect ENT - Point72 Asset Management disclosed a 5.4% stake in Intersect ENT, which represents 1.7M shares. The filing does not allow for activism.

16:54 EDT Boston Scientific reports 'acute' results from UNTOUCHED study - Boston Scientific announced acute results from the UNTOUCHED study evaluating safety and efficacy of the EMBLEM Subcutaneous Implantable Defibrillator System for primary prevention of sudden cardiac death specifically in patients with a left ventricular ejection fraction less than or equal to35%, the most common population to be indicated for ICD therapy. The data were presented during a late-breaking clinical trial at Heart Rhythm 2019, the Heart Rhythm Society's 40th Annual Scientific Sessions in San Francisco, and demonstrated S-ICD therapy had a complication-free rate of 95.8% at 30 days post-procedure and high conversion efficacy of induced ventricular fibrillation, rates comparable to those seen in previous S-ICD and transvenous implantable cardioverter-defibrillator studies. The analysis was also published online today in the Heart Rhythm Journal. The UNTOUCHED study authors also reviewed procedure techniques and 30-day outcomes in patients implanted with the EMBLEM S-ICD System and found that the majority of procedures were performed using a two-incision technique. The two-incision technique data demonstrated a mean implant time of 55.8 minutes, which was 8 minutes faster than the mean 63.8 minutes for procedures that leveraged a three-incision implant technique, with comparable complication and conversion success rates. "We found that the complication rate within this primary prevention population was as low as in prior S-ICD registries, despite the patients having much lower LVEF, more hypertension, and diabetes - underscoring that sicker patients do well with this device for the prevention of sudden death," said Lucas V.A. Boersma, M.D., Ph.D., study principal investigator and electrophysiologist at St. Antonius Hospital, the Netherlands. "These acute outcomes also validate the advantages of the two-incision implant technique, which has continued to gain worldwide adoption in the last few years."

16:33 EDT QuinStreet acquires CloudControlMedia, terms not stated - QuinStreet announced the acquisition of CloudControlMedia, a digital marketing agency based in Annapolis, Maryland. The company states that this acquisition "broadens QuinStreet's market reach and the application of its core technologies via more products and service solutions, outside of its core media marketplace model. The combination enables CloudControlMedia to design and deliver complex marketing campaigns more effectively and at greater scale for its clients utilizing QuinStreet's revolutionary technologies."

16:31 EDT ManpowerGroup raises semi-annual dividend 7.9% to $1.09 per share - The dividend is payable on June 14 to shareholders of record as of the close of business on June 3.

16:24 EDT WageWorks delays 10-Q filing, still working on completing financial statements - In a regulatory filing, WageWorks disclosed that it is "unable to file its quarterly report on Form 10-Q for the quarter ended March 31, 2019 within the prescribed time period without unreasonable effort or expense. As previously announced, the board concluded that the company's internal control over financial reporting and disclosure controls and procedures were ineffective as of December 31, 2017 and that certain financial statements for periods in 2016 and 2017 should be restated and should no longer be relied upon. The company recently filed its financial statements for the fiscal quarters ended September 30, 2018, June 30, 2018 and March 31, 2018 and the Annual Report on Form 10-K for FY17, and its 2016 and 2017 restated financials. As a result of these events and related matters, as previously disclosed, the company experienced a delay in completing its financial statements."

16:07 EDT Karpus Management reports 19% passive stake in OFS Credit - In a regulatory filing, Karpus disclosed a 19% stake in OFS Credit, which represents 152,000 shares. The filing does not allow for activism.

15:46 EDT Travelport says Siris, Evergreen deal delayed due to Russian approval process - In a regulatory filing, Travelport said that, although it obtained shareholder approval of its merger with affiliates of Siris Capital and Elliott's Evergreen Coast Capital and the termination or expiration of applicable waiting periods under the Hart-Scott-Rodino Antitrust Improvement Act of 1976, as amended, and the competition laws of Austria, Germany, Portugal, South Africa and Turkey, consummation of the merger is subject to the satisfaction of additional conditions that may not occur, including approval under the competition laws in Russia. Russian regulatory and governmental entities may impose conditions on the granting of such approval and, if such regulatory and governmental entities seek to impose such conditions, lengthy negotiations may ensue among such regulatory or governmental entities, Siris, Elliott and Travelport. The process of obtaining Russian approval has had the effect of delaying completion of the merger, and such approval may not be received and conditions thereto may not be satisfied for an extended period of time. The obligation to consummate the Merger is also subject to the accuracy of representations and warranties, and the satisfaction of performance of obligations, in each case as set forth in the Merger Agreement, subject to specified materiality exceptions. The obligations of Siris and Elliott to close are also subject to the absence of any material adverse effect on us. As a result of the above-mentioned conditions and the other conditions described in the Merger Agreement, there can be no assurance that the merger will be consummated. Should the merger fail to close for any reason, our business, financial condition, operating results, or cash flows may be materially adversely affected.

15:26 EDT T Rowe Price reports 11.2% passive stake in Tradeweb Markets - T Rowe Price disclosed a 11.2% stake in Tradeweb Markets, which represents 5.17M shares. The filing does not allow for activism.

14:28 EDT Nobilis Health reports resignation of CEO James Springfield - In a regulatory filing, Nobilis Health disclosed that on May 7, James Springfield resigned as CEO of the company, effective immediately, and is no longer an employee of the company.

13:48 EDT Bed Bath & Beyond says willing to 'engage constructively' with activist group - Bed Bath & Beyond issued a statement in response to the decision by Legion Partners Asset Management, Macellum Advisors and Ancora Advisors, collectively referred to as the "activist group," to reduce its slate of nominees to stand for election at the company's 2019 annual meeting of shareholders from 16 to 10, and the activist group's subsequently filed complaint in the United States District Court for the Southern District of New York against Bed Bath & Beyond and its directors. The company stated in part: "As part of our effort to constructively engage with the Activist Group, we have been asking for their input on our business plan and governance, including inviting them to participate in our Board transformation, and continually asking them to disclose who they actually intended to nominate to the Board. After consistently refusing to engage in good faith on these matters, the Activist Group has now finally disclosed who they intend to nominate, and have reduced their 16-person list for our 10-person Board to 10 nominees. Regarding the complaint filed by the Activist Group with respect to the double-trigger change-of-control provision in the Company's Indenture, the Company has never said that it would not approve the Activist Group's candidates once they were finally named, but rather stated that the Board was considering the request and would act in a manner consistent with the Company's obligations under the Indenture...We continue to request that the Activist Group allow the Board, which as of May 1, 2019, includes five new independent directors, to interview their nominees for this purpose. If the Activist Group continues to refuse to let us interview their 10 nominees, the Board will be compelled to assess each of the nominees based solely on information that is publicly available and consistent with the Company's obligations under the Indenture. Bed Bath & Beyond has attempted to settle with the Activist Group on several occasions and we remain ready and willing to engage constructively with the Activist Group to reach a resolution."

13:45 EDT LTSE announces SEC approval for registration as national securities exchange - On May 10, the Securities and Exchange Commission approved the Long-Term Stock Exchange's application for registration as a national securities exchange, "making the exchange one of only a handful of U.S. exchanges qualified to conduct listings and authorizing the company to operate a platform for buying and selling shares," the LTSE announced on its website. "In short, we are building a market where companies are rewarded for choosing to innovate, to invest in their employees, and to seed future growth. And where companies can run their businesses with the stewardship that similarly aligned shareholders, stakeholders and society demand. Our vision is that companies in every industry will be able to go public while continuing to prioritize and pursue strategies for long-term success. That's a step forward for all of us," CEO and founder Eric Ries wrote in the post announcing the SEC approval. Publicly-traded stock exchange operators include Nasdaq (NDAQ) and IntercontinentalExchange (ICE), the owner of the NYSE. Reference Link

13:04 EDT Ameren Missouri to acquire third wind generation facility in Missouri - Ameren Missouri, a subsidiary of Ameren Corporation, announced that it has entered into an agreement to acquire, after construction, a third wind generation facility in Missouri. The facility, developed by Tradewind Energy, an Enel Green Power company, will be located in Atchison County. When operational in 2020, the 300 MW wind facility will power 90,000 homes. It will be located near the town of Tarkio and is scheduled to join two other planned Ameren Missouri-owned wind generation facilities; one will be in Atchison County near the town of Rock Port, and the other, the state's largest, will stretch across Adair and Schuyler Counties. Before construction of the third facility, Ameren Missouri must obtain the Missouri Public Service Commission's review and approval. All three planned facilities remain subject to a number of conditions including obtaining timely and acceptable transmission interconnection agreements from the applicable regional transmission organizations.

12:48 EDT Thyssenkrupp proposes to not proceed with planned separation - Thyssenkrupp said that it and Tata Steel expect that the planned joint venture of their European steel activities will not go ahead due to the Commission's continuing concerns. The European Commission took the improvements of the submitted covenants proposed by thyssenkrupp and Tata Steel as an opportunity to conduct another market test. The new market survey did not resolve the Commission's concerns, although the partners had offered significant further concessions. From the point of the view of thyssenkrupp and Tata Steel, further commitments or improvements would adversely affect the intended synergies of the merger to such an extent that the economic logic of the joint venture would no longer be valid. Consequently, the partners assume that the European Commission will not approve the joint venture. With the expected unsuccessful outcome of the steel joint venture, the Executive Board of thyssenkrupp AG has reassessed the strategic options for the company and will propose to the Supervisory Board to not go ahead with the planned separation into two independent companies. The economic downturn and its effects on business development and the current capital market environment have led to the separation not being able to be realized as planned, the company said. Instead, Thyssenkrupp said it will "fundamentally realign itself to significantly improve its operating performance." This will include a value based more flexible portfolio approach with greater freedom for the development of all businesses, a leaner holding structure and a stronger performance orientation. At the same time, the company will sustainably strengthen its capital base in order to gain the necessary financial leeway for necessary restructuring and business development. As part of this new strategy, the Executive Board of thyssenkrupp AG will also propose an IPO of Elevator Technology to the Supervisory Board. Due to this development, expected book equity gains from the closing of the Steel Joint Venture will not materialize.

12:24 EDT Chico's to review $3.50 per share unsolicited proposal from Sycamore Partners - Chico's FAS confirmed that it has received an unsolicited proposal from Sycamore Partners to acquire the company for $3.50 per share in cash. Chico's said its board of directors "will carefully review the proposal to determine the course of action that it believes is in the best interests of Chico's FAS shareholders." The company noted that it had recently received and rejected an unsolicited proposal from Sycamore to acquire Chico's FAS for $4.30 per share in cash. "Consistent with its fiduciary duties, the board carefully reviewed the prior proposal. Following this review, the board unanimously determined that the prior proposal substantially undervalued Chico's FAS and was not in the best interests of Chico's FAS shareholders," the company stated in a press release.

12:12 EDT Uber CFO says no plans to raise more capital, more do some more debt - Nelson Chai is speaking on CNBC.

12:05 EDT Uber CFO says 'confident' in road, but 'lots of execution' - Nelson Chai is speaking on CNBC.

12:00 EDT Yelp falls -15.9% - Yelp is down -15.9%, or -$6.32 to $33.41.

12:00 EDT GP Strategies rises 9.1% - GP Strategies is up 9.1%, or $1.19 to $14.24.

12:00 EDT Buckeye Partners rises 28.4% - Buckeye Partners is up 28.4%, or $9.26 to $41.81.

11:53 EDT Teva announces launch of generic version of Delzicol capsules in the U.S. - Teva Pharmaceutical Industries announced the launch of a generic version of Delzicol delayed-release capsules, 400 mg, in the U.S. Mesalamine Delayed-Release Capsules are an aminosalicylate indicated for the treatment of mildly to moderately active ulcerative colitis in patients 5 years of age and older, and for the maintenance of remission of ulcerative colitis in adults. Delzicol delayed-release capsules have annual sales of approximately $130M in the U.S., according to IMS data as of February 2019.

10:50 EDT Enzo Biochem announces issuance of U.S. patent for Ozanimod - Enzo Biochem (ENZ) announced that on May 7, it was issued U.S. Patent No. 10,278,960 entitled "Sphingosine Pathway Modulating Compounds for the Treatment of Cancers" that is directed to methods for treating hepatocellular carcinoma, the most common human liver cancer, using the compound Ozanimod. Elazar Rabbani, CEO of Enzo stated, "Our findings with Ozanimod provide further validation for targeting the sphingosine pathway in hepatocellular carcinoma and complement our current program to develop Enzo's proprietary sphingosine kinase inhibitor, SK1-I, for the treatment of HCC. Animal xenotransplantation studies examining the efficacy of each of SK1-I and Ozanimod against tumors derived from human liver cancer cells are currently in progress." Ozanimod is a product of Celgene (CELG) that is in late-stage clinical development for the treatment of relapsing multiple sclerosis and inflammatory bowel disease.

10:34 EDT Quorum drops after disclosing 'substantial doubt' on remaining 'going concern' - Quorum Health (QHC) shares are moving lower after the company disclosed in its quarterly filing that recent events "raised substantial doubt" about its ability to continue as a "going concern." Quorum Health stated, "In accordance with Accounting Standard Codification 205-40, Presentation of Financial Statements - Going Concern, management concluded that there were probable conditions or events that raised substantial doubt about the Company's ability to continue as a going concern due to the fact that the Company's maximum Secured Net Leverage Ratio permitted under the CS Agreement is reduced to 4.50 from 5.00 in the first quarter of 2020. The Company is in compliance with its financial covenants as of March 31, 2019 and believes that it is probable that the Company's current and anticipated future operating results alleviate the substantial doubt about the Company's ability to continue as a going concern for the one year period following the date these financial statements are issued." Quorum Health added that its recent agreement with R1 RCM (RCM), which includes end-to-end revenue cycle management services, should achieve costs savings and improve its net patient revenues through improvements in operational effectiveness and efficiencies. Quorum shares are down 7%, or 15c, to $1.93 in morning trading.

10:09 EDT Avon Products up 7% in early trading - Shares of Avon Products are up 7%, or 19c, to $3.09 in early trading. On April 25, Valor Economico's Vanessa Adachi reported that Natura was in advanced talks to acquire Avon and a deal could be announced soon. Previously, Natura Cosmeticos has confirmed the company was in discussions with Avon Products about a potential transaction. Today's strength could be related to a new article on an Avon deal that has been published by Intereconomia. Reference Link

09:57 EDT Halcon says hired advisors in March to help evaluate strategic alternatives - Halcon said yesterday that in late March it engaged Tudor Pickering and Holt and Perella Weinberg Partners to assist the company in evaluating strategic and financial alternatives. These alternatives may include the sale or merger of the company, select asset sales and/or other financing options that would replace the Halcon's existing senior revolving credit facility, Halcon said in a statement. The company does not expect to comment further unless and until a specific transaction is approved by its Board of Directors or the company otherwise decides further disclosure is appropriate or required.

09:47 EDT Nevro falls -8.8% - Nevro is down -8.8%, or -$5.55 to $57.21.

09:47 EDT Jumia Technologies falls -16.0% - Jumia Technologies is down -16.0%, or -$4.29 to $22.60.

09:47 EDT Cars.com rises 4.6% - Cars.com is up 4.6%, or 96c to $21.78.

09:32 EDT Viacom says all affiliate deals have annual escalators - Says: Huge demand for film product in China... Don't expect long-term problems in China... "Tremendously excited" about Paramount.

09:18 EDT Cinedigm acquires North American rights to 'Teacher' - Cinedigm announced that it has acquired North American rights to the psychological thriller "Teacher". Written and directed by Adam Dick, the film stars David Dastmalchian and Kevin Pollak.

09:10 EDT Motorola Solutions says USPTO upholds patents against Hytera challenges - Motorola Solutions announced that the Patent Trial and Appeal Board of the United States Patent and Trademark Office issued final written decisions in the Inter Partes Reviews of Motorola Solutions' U.S. Patent Nos. 8,116,284 and 6,591,111, which relate to Motorola Solutions' time-division multiple access and group radio communication system technology, respectively. The PTAB rejected all validity challenges against U.S. Patent No. 8,116,284 raised by Hytera Communications Corporation Limited. In addition, the PTAB upheld the validity of a number of the claims of U.S. Patent No. 6,591,111 challenged by Hytera. Both of these patents are asserted against Hytera's i-Series and older products in Motorola's patent infringement case pending against Hytera in the Northern District of Illinois. Late last year, the U.S. International Trade Commission also ruled that Hytera's pre-i Series Digital Mobile Radio products infringe four Motorola patents, including U.S. Patent No. 8,116,284. That ruling is now final. The functionality provided by these patents is particularly important in emergency and life-threatening situations, including techniques to: Efficiently use DMR channels by allowing devices to temporarily select a different timeslot when the default timeslot is busy, which increases the number of calls that can take place and significantly reduces the amount of time it takes to set up a new call; and Enable efficient group communications between multiple talkgroups, even if those talkgroups use incompatible protocols.

09:07 EDT Eastside Distilling launches Burnside Whiskey, bourbon lineup in California - Eastside Distilling announced the Burnside lineup of bourbons and whiskeys will be launched into the state of California effective immediately. The multiple award-winning lineup includes the Burnside Oregon Oaked Bourbon, Burnside West End Blend, Burnside Oregon Oaked Rye, and Burnside Goose Hollow RSV Bourbon.

09:06 EDT Lydall divests geosynthetic installation business - Lydall, through its wholly-owned subsidiary Texel Technical Materials, announced that it completed the sale of Texel Geosol to FC Geosynthetiques. Geosol installs geosynthetic products in the civil engineering and environmental protection sectors, principally within the province of Quebec, Canada.

09:02 EDT Fly Intel: Pre-market Movers - UP AFTER EARNINGS: Viacom (VIAB), up 1%... JD.com (JD), up 7%... Dropbox (DBX), up 6%... Zillow (ZG), up 15%... CarGurus (CARG), up 7%. DOWN AFTER EARNINGS: Nabriva Therapeutics (NBRV), down 1%... TransEnterix (TRXC), down 31%... Symantec (SYMC), down 15%... Maxar Technologies (MAXR), down 15%... Aqua Metals (AQMS), down 21%.

08:50 EDT Viacom says backs FY domestic affiliate growth - Says: Flagship brands gaining "significant traction" on mobile networks... Pluto TV showing strong early momentum... Expanding Pluto TV in Europe, Latin America... Has signed second deal with distributor for Pluto TV.

08:39 EDT Viacom says 'particularly pleased' with progress in distribution - Says: Sees strong return to growth in second half of year... Flagship networks continue to deliver... Expects to deliver domestic ad sales growth in Q3... Advanced marketing business will double sales in 2019. Comments from company's Q2 earnings conference call.

08:32 EDT T. Rowe Price reports preliminary AUM of $1.11T as of April 30 - T. Rowe Price reported preliminary month-end Assets Under Management of $1.11t as of April 30. Client transfers from mutual funds to other portfolios, including trusts and separate accounts, were $2.4B in April 2019 and $8.5B for the year-to-date period ended April 30, 2019.

08:20 EDT Galectin Therapeutics releases Richard Uihlein's open letter to stockholders - Galectin Therapeutics released this open letter to stockholders written by its Board Chair Richard E. Uihlein. The letter reads as follows in part: "As Chairman of Galectin Therapeutics, once again I wanted to address you directly. On April 15th the Company announced the record date, closing date and pricing of the rights offering. I wanted to share my thoughts about the offering and our rationale for the pricing. Also, I felt I should describe, from my perspective, how the offering will work. Simply put, at this point in our history, we need to fund our Phase-3 clinical trial in patients with NASH cirrhosis. Not many companies are fortunate enough to advance a new drug compound this far. Today we are well advanced into the trial design, and we are looking forward to getting the trial underway. For that I want to thank our team led by our CEO, Harold Shlevin, and our employees and researchers. I am a long-term investor who clearly believes in the Company but joining the board has given me a new degree of respect and understanding of the complexity involved in the clinical trial process. I am extremely grateful to all involved.I want to reiterate the conviction of my commitment to the Company on several levels. My invitation to our stockholders is to make an investment along side of me in a science-driven enterprise. I take all investments, including money and time, extremely seriously, and I urge everyone to do the same. This is especially the case for me in this endeavor because I am the Board's Chairman.My belief in the Company, the Board, management and our team, is in addition to my belief in and the commitment to our science. Neither I as Chairman nor our Board has or can make a recommendation to you about whether you should invest. However, speaking as the Company's largest individual stockholder, I felt it was important to state my rationale for my personal investment in this rights offering...After reviewing reports of our Phase 2 data and the researchers' comments with respect to our outcome, I was extremely encouraged. A statistically meaningful reduction in portal pressure measured by HVPG has never been observed in a Phase 2 NASH trial in any patient population. While we obtained this outcome in only a subsection of our trial participants, it was, and is, a meaningful population. Additionally, the most promising data from my perspective, and, not coincidentally, the primary endpoint in our Phase 3 trial, was the potential to prevent varices in NASH patients who had yet to develop them. This also has never been achieved in any Phase 2 NASH trial. These are not only my words or beliefs. Please read the comments made by our research team and analysts...My request to you regardless of your desire to participate in our rights offering, is to seriously consider the consequences of loaning your shares, and its potential impact on your investment. I would also request that you consider the potential impact of holding your shares in margin accounts. I do not make this request due to the fact that I begrudge stock speculation. I believe at my core in free market capitalism. That same belief gives me the ability to speak in opposition to those who do not share in my vision for the Company.Thank you for your time and your confidence in me. My sincere hope is that you understand my intention and my commitment to you as my fellow shareholders and co-investors."Sincerely, Richard E Uihlein

08:16 EDT Atlantica Yield increases quarterly dividend 5% to 39c per share - The board of directors of Atlantica approved a dividend of 39c per share which represents a 22% increase with respect to Q1 2018 and 5% compared with Q4 of 2018. This dividend is expected to be paid on June 14 to shareholders of record as of June 3.

08:13 EDT Fat Brands debuts Impossible Burger in Singapore - FAT Brands will debut a new menu item, the Impossible Burger at all Singapore locations. A huge success across the United States, the 'bleeding,' vegan-friendly burger is available at Fatburgers across the USA, as well as sister brands Hurricane Grill & Wings and Buffalo's Cafe.

08:11 EDT Planet Green Holdings to acquire Xianning Bozhuang Tea Products - Planet Green Holdings and its wholly owned subsidiary Shanghai Xunyang Internet entered into a Share Exchange Agreement with Xianning Bozhuang Tea Products and each of the shareholders of Xianning pursuant to which the subsidiary will acquire all outstanding equity interests of Xianning, a company that produces tea products and sells such products in China. The company will issue an aggregate of 1,080,000 shares of common stock of the company to the sellers in exchange for the transfer of all of the equity interest of Xianning to the subsidiary. As of the closing, the company's board of directors will consist of five individuals, including one person that will be designated by Xianning.

08:08 EDT Forty Seven and Acerta in pact to evaluate novel immuno-oncology combination - Forty Seven Inc., a clinical-stage immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today announced a collaboration with Acerta Pharma, AstraZeneca's hematology research and development center of excellence. Under the terms of the collaboration, Acerta will sponsor a clinical trial evaluating Forty Seven's CD47 antibody 5F9 in combination with rituximab plus Acerta's CALQUENCE in patients with diffuse large B-cell lymphoma, an aggressive form of non-Hodgkin's lymphoma (NHL). This study aims to build upon the promising results already reported from a Phase 1b study of 5F9 in combination with rituximab in NHL patients by including a third agent, acalabrutinib, to further optimize the treatment of DLBCL patients. "We are looking forward to evaluating this novel triple combination of 5F9 and rituximab with acalabrutinib. With acalabrutinib, we have a compound that optimally targets Bruton tyrosine kinase," said Andrew Mortlock, Chief Scientific Officer at Acerta Pharma. "We established the PRISM platform study in 2018 with the explicit goal of exploring novel combinations and are pleased to be able to collaborate with Forty Seven to include 5F9 in this platform and bring this innovative combination of therapies to patients." "This combination of immunotherapy with targeted therapy has the potential to help patients with an aggressive type of lymphoma. These individual therapies have previously demonstrated activity in lymphoma without the toxicities associated with traditional cytotoxic chemotherapy," added Ian W. Flinn, M.D., Ph.D., Chair of the PRISM Study and Director of the Lymphoma Research Program at Sarah Cannon Research Institute.

08:07 EDT Manning & Napier reports preliminary AUM of $21.2B as of April 30 - AUM as of March 31 was $21.1B.

08:02 EDT Ball Corp. authorizes $250M accelerated stock repurchase - Ball announced an agreement to repurchase approximately $250M of its outstanding common stock in a privately negotiated, accelerated stock repurchase transaction with Citibank N.A., using cash on hand and available borrowings. Subject to certain conditions, the transaction will commence today and reduce Ball's outstanding common stock by a total of approximately 4 million shares. Following the completion of the transaction, 45 million shares remain available for repurchase under the company's existing authorization.

07:45 EDT PolarityTE's SkinTE for ulcers featured in two studies - PolarityTE announced today data from two pilot studies on the use of its SkinTE product both showing successful closure of diabetic foot ulcers and venous stasis leg ulcers within a 12-week period. The cases involved patients with lower extremity chronic wounds that were difficult to treat or had failed to heal with standard dressing care and conventional treatments, using a single application of SkinTE. The data was presented at the Symposium on Advanced Wound Care spring conference in San Antonio, TX. SkinTE is a first-of-its-kind autologous, homologous human cellular and tissue-based product designed to regenerate full-thickness, functional skin for the repair, reconstruction and replacement of a patient's own skin. All patients had wounds resistant to standard dressing care. The chronic wounds in 10 of the 11 patients with DFUs and all five VLU patients demonstrated granulation, progressive epithelialization and closure within 12 weeks following a single application of SkinTE. The wounds remained closed, with no adverse reactions, during follow-up visits at least 14 weeks post initial SkinTE application. The studies are pilots for two multi-center, randomized controlled clinical trials evaluating SkinTE for DFUs and VLUs that are currently enrolling patients.

07:35 EDT Flexion announces pooled analysis of Zilretta data published - Flexion announced that a pooled analysis of data from three Phase 2/3 randomized clinical trials on the use of rescue medications with Zilretta were published in Pain and Therapy. The analysis indicated that rescue medication use was lower following a single injection of Zilretta, the first and only extended-release intra-articular therapy for OA knee pain, in comparison to placebo and TAcs. In clinical trials that evaluate the efficacy of pain therapies, rescue medications, such as acetaminophen, may generally be used by patients to manage acute episodic pain when the primary treatment is not providing sufficient relief. Measuring rescue medication use can provide important information on the robustness of the overall analgesic effect, as effective pain medications should reduce the need for rescue medications and lower the cumulative exposure to potentially harmful side effects. The overall number of rescue medication tablets used per day through Week 24 was less for Zilretta compared to saline-placebo and TAcs. The safety profile of Zilretta in this pooled analysis was consistent with that of the pivotal Phase 3 trial.

07:33 EDT E.W. Scripps sees Q2 pro forma local media revenue $245M-$250M - Sees Q2 pro forma national media revenue low to mid $90M range. Q2 revenue consensus $345.07M.

07:25 EDT JD.com up 10% to $30.32 after Q1 results beat estimates

07:20 EDT JetBlue sees Q2 RASM up 1%-4%

07:14 EDT Enbridge backs FY19 DCF per share view C$4.30-C$4.60

07:07 EDT Pareteum launches seven new customers in April - Pareteum launched seven new customers into production during April. The seven new customers now powering their commercial services with Pareteum solutions are: an Internet of Things service provider using the Pareteum SuperAPI to connect to the Pareteum global network; a developer of a global blockchain-based Wi-Fi sharing community; a provider of mobility services; a mobile voice and broadband services provider to international enterprise and consumer markets using Pareteum's cloud platform, SIM solutions, and network capabilities to deliver services in the US, Australia, and New Zealand; a Pay-TV and broadband provider using the Pareteum solutions to extend its bundled offering to include mobile services; a US Mobile Virtual Network Operator and provider of virtual PBX services using the Pareteum platform and network to power services to the B2B market; a UK Mobile Virtual Network Operator using the Pareteum cloud platform, network, and SuperAPI to power consumer services.

07:02 EDT Bruker announces new $300M share repurchase program - Bruker announced that on May 9, its Board of Directors approved a new share repurchase authorization for the purchase of up to $300M of the company's common stock over a two-year period commencing May 14.

06:54 EDT JD.com reports annual active customer accounts increased to 310.5M - Annual active customer accounts increased to 310.5M in the twelve months ended March 31, from 305.3M in the twelve months ended December 31, 2018. Quarterly active customer accounts in the first quarter increased by 15% as compared to the same period in 2018.

06:49 EDT Lazard reports preliminary AUM approximately $239.6B as of April 30 - The month's AUM included market appreciation of $6.6B; net outflows of $1.3B; and foreign exchange depreciation of $0.6B.

06:48 EDT NuStar Energy selling St. Eustatius terminal for $250M - NuStar Energy plans to sell its St. Eustatius Terminal. "Today, we are pleased to announce that we have signed a definitive stock purchase agreement to sell our storage terminal facility located at St. Eustatius in the Caribbean to Prostar Capital for approximately $250M, subject to adjustment," said Brad Barron, president and CEO of NuStar Energy L.P. "We are pleased that this sale allows us to re-deploy the sales proceeds to improve our financial metrics and fund our growth projects for our core business in North America (...) We expect to close this transaction by the end of the second quarter, and we look forward to focusing all of our resources on strengthening our financial metrics to generate stable, consistent growth for our unitholders," said Barron.

06:35 EDT Obsidian Energy backs FY19 production view 26,750-27,750 Boepd

06:19 EDT Elizabeth Warren cheers Chris Hughes' call to break up Facebook - Sen. Elizabeth Warren, the Massachusetts Democrat who is running for president in 2020, is cheering a call by Facebook co-founder Chris Hughes to break up the company into three different businesses. She said via Twitter: "Chris Hughes is right. Today's big tech companies have too much power-over our economy, our society, & our democracy. They've bulldozed competition, used our private info for profit, hurt small businesses & stifled innovation. It's time to #BreakUpBigTech." Reference Link

06:06 EDT Aslan Pharmaceuticals signs agreement with K-MASTER to investigate varlitinib - Aslan Pharmaceuticals announced that it has signed an agreement with the Korean Cancer Diagnosis & Treatment Enterprise to investigate varlitinib in a phase 1b/2 multi-centre umbrella study to evaluate the safety and efficacy of varlitinib in combination with weekly paclitaxel as a second-line treatment in HER1/HER2 co-expressing advanced or metastatic gastric cancer patients. The two-part, phase 1b/2, open label, multi-centre study will recruit approximately 400 patients, divided between four experimental arms and a common control arm based on biomarker profiling. Patients that are HER1/HER2 co-expressing will receive varlitinib in combination with weekly paclitaxel. Other arms will test PD1 and PI3K-beta inhibitors. The study, led by Professor Sun Young Rha of the Yonsei Cancer Center, will be conducted in up to 10 sites in South Korea.

06:03 EDT Changyou.com announces ex-dividend date of June 3 for special cash dividend - Changyou.com announced that Nasdaq has established June 3 as the ex-dividend date for Changyou's previously-announced special cash dividend of $9.40 per American depositary share, based on a payment date of May 31. Accordingly, in order to be entitled to receive this special dividend, holders of ADSs must hold the ADSs through the end of the payment date. The company expects The Bank of New York Mellon, the depositary bank for the company's ADS program, to distribute the dividend on or about the payment date to holders of ADSs as of the end of the payment date.

05:55 EDT TerraForm Power CEO says 'confident' in achieving growth target - "During the first quarter of 2019, we made significant progress completing our margin enhancement initiatives, which we expect will cover approximately 75% of the growth required to achieve our 5% to 8% annual dividend increase target through 2022 with a payout ratio of 80% to 85% of CAFD," said John Stinebaugh, CEO of TerraForm Power. "With only a modest amount of organic growth investments funded by internally generated cash flow required to fill the remaining gap, we are confident in our ability to achieve our growth target and enhance shareholder value."